Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DW3J9N
|
|||
| Drug Name |
DACRA 089
|
|||
| Synonyms |
KBP-089
Click to Show/Hide
|
|||
| Drug Type |
Peptide
|
|||
| Indication | Type 2 diabetes [ICD-11: 5A11; ICD-10: E08-E13] | Phase 1 | [1] | |
| Company |
Eli Lilly
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Amylin receptor (IAPPR) | Target Info | Agonist | [2] |
| Calcitonin receptor (CALCR) | Target Info | Agonist | [2] | |
| KEGG Pathway | Vascular smooth muscle contraction | |||
| Neuroactive ligand-receptor interaction | ||||
| Osteoclast differentiation | ||||
| NetPath Pathway | RANKL Signaling Pathway | |||
| Reactome | G alpha (s) signalling events | |||
| Calcitonin-like ligand receptors | ||||
| WikiPathways | GPCRs, Class B Secretin-like | |||
| RANKL/RANK Signaling Pathway | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03907202) A Clinical Study to Evaluate the Safety, Tolerability, PK, PD, and Efficacy of KBP-089 in Patients With T2DM. U.S. National Institutes of Health. | |||
| REF 2 | A novel dual amylin and calcitonin receptor agonist, KBP-089, induces weight loss through a reduction in fat, but not lean mass, while improving food preference. Br J Pharmacol. 2017 Apr;174(7):591-602. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.